LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

Home・Akcijų sąrašas・AstraZeneca PLC

AstraZeneca PLC

Atidarymo kaina

SektoriusSveikatos priežiūra

187.7 -1.29

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

186.25

Max

189.72

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.6B 3.9B
Pardavimai	-215M 15B
P/E Sektoriaus vid.	27.887 49.701
Pelnas, tenkantis vienai akcijai	1.29
Dividendų pajamingumas	1.74
Pelno marža	25.602
Darbuotojai	96,100
EBITDA	1.1B 5.7B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+15.23% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.74% 2.39%
Kitas uždarbis	2026-07-27
Kita Ex Dividend data	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-3.5B 287B
Ankstesnė atidarymo kaina	188.99
Ankstesnė uždarymo kaina	187.7

Naujienos nuotaikos

By Acuity

34%

66%

81 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

N/A / 69.55 Palaikymas ir pasipriešinimas

AstraZeneca PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 16:28; UTC

Uždarbis

Correction to AstraZeneca Update

2026-04-29 15:11; UTC

Uždarbis

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

2026-04-29 06:31; UTC

Uždarbis

AstraZeneca Gets Revenue Boost From Cancer Drugs

2026-05-21 11:06; UTC

Rinkos pokalbiai

AstraZeneca Set for Busy End of Year -- Market Talk

2026-05-13 12:29; UTC

Rinkos pokalbiai

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

2026-05-13 11:54; UTC

Rinkos pokalbiai

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

2026-05-01 09:31; UTC

Rinkos pokalbiai

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

2026-04-29 10:29; UTC

Rinkos pokalbiai

Uždarbis

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

2026-04-29 10:06; UTC

Rinkos pokalbiai

Uždarbis

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

2026-04-29 09:53; UTC

Rinkos pokalbiai

Uždarbis

AstraZeneca Seems in Fine Health -- Market Talk

2026-04-29 06:05; UTC

Uždarbis

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

2026-04-29 06:04; UTC

Uždarbis

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

2026-04-29 06:04; UTC

Uždarbis

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

2026-04-29 06:03; UTC

Uždarbis

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

2026-04-29 06:03; UTC

Uždarbis

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

2026-04-29 06:02; UTC

Uždarbis

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

2026-04-29 06:01; UTC

Uždarbis

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

2026-04-29 06:01; UTC

Uždarbis

AstraZeneca Backs 2026 View

2026-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Adj EPS $2.58

2026-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Rev $15.29B

2026-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Pretax Pft $3.91B

2026-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Oper Pft $4.25B

2026-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q Net Pft $3.08B

2026-04-29 06:00; UTC

Uždarbis

AstraZeneca PLC 1Q EPS $1.97

2026-04-27 10:48; UTC

Rinkos pokalbiai

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

2026-04-10 11:57; UTC

Rinkos pokalbiai

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

2026-04-10 10:26; UTC

Rinkos pokalbiai

Uždarbis

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2026-04-02 09:16; UTC

Rinkos pokalbiai

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

2026-03-27 10:40; UTC

Rinkos pokalbiai

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

2026-03-27 10:17; UTC

Rinkos pokalbiai

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Akcijų palyginimas

Kainos pokytis

AstraZeneca PLC Prognozė

Kainos tikslas

By TipRanks

15.23% į viršų

12 mėnesių prognozė

Vidutinis 216.011 USD 15.23%

Aukščiausias 249.911 USD

Žemiausias 151.828 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AstraZeneca PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių AstraZeneca PLC akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 69.55Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

81 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.